

Cameron W Brennan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9127397/publications.pdf>

Version: 2024-02-01

157
papers

60,081
citations

6606

79
h-index

6990

154
g-index

159
all docs

159
docs citations

159
times ranked

63053
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of tract recurrence with stereotactic biopsy of brain metastases: an 18-year cancer center experience. <i>Journal of Neurosurgery</i> , 2022, 136, 1045-1051.	0.9	7
2	Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. <i>Developmental Cell</i> , 2022, 57, 32-46.e8.	3.1	71
3	The Evolution of 5-Aminolevulinic Acid Fluorescence Visualization: Time for a Headlamp/Loupe Combination. <i>World Neurosurgery</i> , 2022, 159, 136-143.	0.7	6
4	Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma. <i>Clinical Cancer Research</i> , 2022, 28, 2938-2952.	3.2	11
5	Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control. <i>Neuro-Oncology Practice</i> , 2021, 8, 278-289.	1.0	22
6	Mechanisms of stearyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. <i>Science Advances</i> , 2021, 7, .	4.7	38
7	PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. <i>Molecular Cell</i> , 2021, 81, 1276-1291.e9.	4.5	54
8	The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. <i>Journal of Neuro-Oncology</i> , 2021, 153, 507-518.	1.4	20
9	Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes. <i>Journal of Neuro-Oncology</i> , 2021, 154, 301-313.	1.4	8
10	SURG-03. The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. <i>Neuro-Oncology Advances</i> , 2021, 3, iii23-iii24.	0.4	0
11	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. <i>JCI Insight</i> , 2021, 6, .	2.3	10
12	Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation. <i>Journal of Neuro-Oncology</i> , 2021, 155, 277-286.	1.4	16
13	¹⁸ F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1446-1457.	3.3	13
14	Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics. <i>Clinical Cancer Research</i> , 2020, 26, 5424-5437.	3.2	21
15	Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1742-1756.	0.6	18
16	Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. <i>Acta Neuropathologica Communications</i> , 2020, 8, 186.	2.4	26
17	Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. <i>Cell</i> , 2020, 181, 1643-1660.e17.	13.5	554
18	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, e1837-e1845.	1.9	21

#	ARTICLE	IF	CITATIONS
19	Ultrasml Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. <i>Clinical Cancer Research</i> , 2020, 26, 147-158.	3.2	59
20	Cell Lineage-Based Stratification for Glioblastoma. <i>Cancer Cell</i> , 2020, 38, 366-379.e8.	7.7	68
21	LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement. <i>Neuro-Oncology</i> , 2020, 22, 1315-1326.	0.6	17
22	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. <i>International Journal of Particle Therapy</i> , 2020, 6, 17-28.	0.9	24
23	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	3.2	107
24	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. <i>Oncoimmunology</i> , 2019, 8, e1655360.	2.1	76
25	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. <i>Nature</i> , 2019, 565, 654-658.	13.7	361
26	EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 337-345.	1.4	30
27	Sequencing and curation strategies for identifying candidate glioblastoma treatments. <i>BMC Medical Genomics</i> , 2019, 12, 56.	0.7	7
28	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. <i>Cancer Discovery</i> , 2019, 9, 756-777.	7.7	18
29	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
30	Incidence of Prolonged Systemic Steroid Treatment after Surgery for Acoustic Neuroma and Its Implications. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, 559-568.	0.4	0
31	Intracranial metastasis in fibrolamellar hepatocellular carcinoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26919.	0.8	4
32	Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes. <i>Neurosurgery</i> , 2018, 83, 76-85.	0.6	31
33	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. <i>Clinical Cancer Research</i> , 2018, 24, 737-743.	3.2	154
34	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.	0.8	39
35	Metabolic Imaging of the Human Brain with Hyperpolarized ¹³ C Pyruvate Demonstrates ¹³ C Lactate Production in Brain Tumor Patients. <i>Cancer Research</i> , 2018, 78, 3755-3760.	0.4	179
36	Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma. <i>Epigenetics</i> , 2018, 13, 432-448.	1.3	29

#	ARTICLE	IF	CITATIONS
37	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. <i>Nature Genetics</i> , 2018, 50, 62-72.	9.4	137
38	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2017, 19, 1380-1390.	0.6	35
39	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	7.7	302
40	Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients. <i>Journal of Neuro-Oncology</i> , 2017, 134, 245-251.	1.4	6
41	Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5 Å– 6 Gy) conformal radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 203-208.	0.3	16
42	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. <i>Cancer Cell</i> , 2017, 32, 506-519.e5.	7.7	240
43	Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas. <i>Glia</i> , 2017, 65, 1914-1926.	2.5	50
44	EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines. <i>Scientific Reports</i> , 2017, 7, 9043.	1.6	27
45	Concurrence of chromosome 6 chromothripsis and glioblastoma metastasis. <i>Journal of Neurosurgery</i> , 2017, 126, 1472-1478.	0.9	4
46	FGFR-TACC approaches the first turn in the race for targetable GBM mutations. <i>Neuro-Oncology</i> , 2017, 19, 461-462.	0.6	2
47	Systematic Combinatorial Chimeric Antigen Receptor Therapies to AML. <i>Blood</i> , 2017, 130, 856-856.	0.6	0
48	Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. <i>Cell Reports</i> , 2016, 17, 2445-2459.	2.9	450
49	Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets. <i>Blood</i> , 2016, 128, 526-526.	0.6	1
50	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. <i>Science Translational Medicine</i> , 2015, 7, 274ra17.	5.8	257
51	CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. <i>Cancer Research</i> , 2015, 75, 1516-1526.	0.4	79
52	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	13.9	2,582
53	Ultrasoft dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7119-7130.	1.4	26
54	Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. <i>Journal of Neuro-Oncology</i> , 2015, 125, 149-156.	1.4	224

#	ARTICLE	IF	CITATIONS
55	Sleeping Beauty Mouse Models Identify Candidate Genes Involved in Gliomagenesis. PLoS ONE, 2014, 9, e113489.	1.1	21
56	Emerging Therapies for Glioblastoma. JAMA Neurology, 2014, 71, 1437.	4.5	148
57	The Somatic Genomic Landscape of Glioblastoma. Cell, 2014, 157, 753.	13.5	51
58	Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathologica, 2014, 127, 747-759.	3.9	26
59	Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology, 2014, 16, 1186-1195.	0.6	69
60	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	9.4	525
61	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	12.8	469
62	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2014, 20, 5023-5031.	3.2	89
63	Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. Cancer Research, 2014, 74, 1429-1439.	0.4	59
64	Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8149-8154.	3.3	80
65	Outcomes and Prognostic Factors in Women With 1 to 3 Breast Cancer Brain Metastases Treated With Definitive Stereotactic Radiosurgery. International Journal of Radiation Oncology Biology Physics, 2014, 90, 518-525.	0.4	28
66	Acute inflammatory reactions to hemostatic materials mimicking post-operative intracranial abscess. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2014, 1, 5-7.	0.2	6
67	A Phase 2 Trial of Stereotactic Radiosurgery Boost After Surgical Resection for Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2014, 88, 130-136.	0.4	218
68	TRIM3, a tumor suppressor linked to regulation of p21Waf1/Cip1. Oncogene, 2014, 33, 308-315.	2.6	51
69	Genomic Analysis of Non- <i>NF2</i> Meningiomas Reveals Mutations in <i>TRAF7</i> , <i>KLF4</i> , <i>AKT1</i> , and <i>SMO</i>. Science, 2013, 339, 1077-1080.	6.0	714
70	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
71	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Proceedings of SPIE, 2013, , .	0.8	2
72	Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class. Clinical Cancer Research, 2013, 19, 4951-4960.	3.2	182

#	ARTICLE	IF	CITATIONS
73	CSF-1R inhibition alters macrophage polarization and blocks glioma progression. <i>Nature Medicine</i> , 2013, 19, 1264-1272.	15.2	1,812
74	An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. <i>Science</i> , 2013, 340, 626-630.	6.0	1,014
75	Double Minute Chromosomes in Glioblastoma Multiforme Are Revealed by Precise Reconstruction of Oncogenic Amplicons. <i>Cancer Research</i> , 2013, 73, 6036-6045.	0.4	94
76	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. <i>Genes and Development</i> , 2013, 27, 1462-1472.	2.7	74
77	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. <i>Oncotarget</i> , 2013, 4, 1729-1736.	0.8	213
78	The role of radiotherapy following gross-total resection of atypical meningiomas. <i>Journal of Neurosurgery</i> , 2012, 117, 679-686.	0.9	160
79	Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3041-3046.	3.3	459
80	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. <i>Nature Genetics</i> , 2012, 44, 1179-1181.	9.4	692
81	microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF- β Signaling in Glioblastoma. <i>Cancer Discovery</i> , 2012, 2, 736-749.	7.7	99
82	Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 458-471.	7.7	304
83	Candidate Pathways for Promoting Differentiation or Quiescence of Oligodendrocyte Progenitor-like Cells in Glioma. <i>Cancer Research</i> , 2012, 72, 4856-4868.	0.4	68
84	Passenger deletions generate therapeutic vulnerabilities in cancer. <i>Nature</i> , 2012, 488, 337-342.	13.7	294
85	MEF Promotes Stemness in the Pathogenesis of Gliomas. <i>Cell Stem Cell</i> , 2012, 11, 836-844.	5.2	37
86	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. <i>Nature Medicine</i> , 2012, 18, 829-834.	15.2	1,029
87	Protein Phosphatase 2A Mediates Dormancy of Glioblastoma Multiforme-Derived Tumor Stem-Like Cells during Hypoxia. <i>PLoS ONE</i> , 2012, 7, e30059.	1.1	55
88	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , 2012, 26, 756-784.	2.7	463
89	Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19024-19029.	3.3	91
90	Integrated genomic analyses of ovarian carcinoma. <i>Nature</i> , 2011, 474, 609-615.	13.7	6,541

#	ARTICLE	IF	CITATIONS
91	Recruited Cells Can Become Transformed and Overtake PDGF-Induced Murine Gliomas In Vivo during Tumor Progression. PLoS ONE, 2011, 6, e20605.	1.1	72
92	Stereotactic Brain Biopsy With a Low-Field Intraoperative Magnetic Resonance Imager. Operative Neurosurgery, 2011, 68, ons217-ons224.	0.4	13
93	Physics, 2011, 38, 2724-2730.	1.6	5
94	Neurosurgery for Brain Tumors: Update on Recent Technical Advances. Current Neurology and Neuroscience Reports, 2011, 11, 313-319.	2.0	81
95	Genomic Profiles of Glioma. Current Neurology and Neuroscience Reports, 2011, 11, 291-297.	2.0	39
96	Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia, 2011, 59, 1190-1199.	2.5	201
97	18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers. Cancer Research, 2011, 71, 5164-5174.	0.4	113
98	Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO Journal, 2011, 30, 4084-4097.	3.5	134
99	Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17, 98-110.	7.7	6,138
100	PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas. Cancer Cell, 2010, 17, 497-509.	7.7	224
101	Loss of ATM/Chk2/p53 Pathway Components Accelerates Tumor Development and Contributes to Radiation Resistance in Gliomas. Cancer Cell, 2010, 18, 619-629.	7.7	211
102	Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. International Journal of Cancer, 2010, 127, 568-577.	2.3	54
103	Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 2010, 468, 829-833.	13.7	1,091
104	Identification of DOK genes as lung tumor suppressors. Nature Genetics, 2010, 42, 216-223.	9.4	105
105	Integrative Genome Comparison of Primary and Metastatic Melanomas. PLoS ONE, 2010, 5, e10770.	1.1	166
106	PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes and Development, 2010, 24, 2205-2218.	2.7	181
107	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes and Development, 2010, 24, 1731-1745.	2.7	454
108	Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6912-6917.	3.3	109

#	ARTICLE	IF	CITATIONS
109	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6459-6464.	3.3	99
110	Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes and Development, 2010, 24, 2194-2204.	2.7	75
111	Advanced Imaging in Brain Tumor Surgery. Neuroimaging Clinics of North America, 2010, 20, 311-335.	0.5	21
112	Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells. Cell Stem Cell, 2010, 6, 141-152.	5.2	493
113	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9435-9440.	3.3	246
114	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes and Development, 2009, 23, 1327-1337.	2.7	465
115	Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations. PLoS ONE, 2009, 4, e7752.	1.1	450
116	Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis. Cancer Cell, 2009, 16, 44-54.	7.7	132
117	An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene, 2009, 28, 2773-2783.	2.6	205
118	PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells. Cell Stem Cell, 2009, 4, 226-235.	5.2	740
119	PRESURGICAL EVALUATION OF LANGUAGE USING FUNCTIONAL MAGNETIC RESONANCE IMAGING IN BRAIN TUMOR PATIENTS WITH PREVIOUS SURGERY. Neurosurgery, 2009, 64, 644-653.	0.6	45
120	Methods for DNA copy number derivations. , 2009, , 25-51.		0
121	Clinical characterization of human metapneumovirus infection among patients with cancer. Journal of Infection, 2008, 57, 464-471.	1.7	49
122	Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455, 1061-1068.	13.7	6,879
123	p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 2008, 455, 1129-1133.	13.7	658
124	Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. Cancer Cell, 2008, 13, 355-364.	7.7	109
125	INTRAOPERATIVE MAGNETIC RESONANCE IMAGING AT 3-T USING A DUAL INDEPENDENT OPERATING ROOM-MAGNETIC RESONANCE IMAGING SUITE. Neurosurgery, 2008, 63, 412-426.	0.6	50
126	Assessment of the Language Laterality Index in Patients with Brain Tumor Using Functional MR Imaging: Effects of Thresholding, Task Selection, and Prior Surgery. American Journal of Neuroradiology, 2008, 29, 528-535.	1.2	81

#	ARTICLE	IF	CITATIONS
127	Pten and p53 Converge on c-Myc to Control Differentiation, Self-renewal, and Transformation of Normal and Neoplastic Stem Cells in Glioblastoma. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2008, 73, 427-437.	2.0	109
128	<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20932-20937.	3.3	1,557
129	Common and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types. <i>Cancer Research</i> , 2007, 67, 10736-10743.	0.4	64
130	Hypofractionated Stereotactic Radiotherapy Using Intensity-Modulated Radiotherapy in Patients with One or Two Brain Metastases. <i>Stereotactic and Functional Neurosurgery</i> , 2007, 85, 82-87.	0.8	76
131	Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. <i>Science</i> , 2007, 318, 287-290.	6.0	849
132	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. <i>Nature</i> , 2007, 447, 966-971.	13.7	355
133	Malignant astrocytic glioma: genetics, biology, and paths to treatment. <i>Genes and Development</i> , 2007, 21, 2683-2710.	2.7	1,952
134	Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5947-5952.	3.3	537
135	A Genome-Wide Screen Reveals Functional Gene Clusters in the Cancer Genome and Identifies EphA2 as a Mitogen in Glioblastoma. <i>Cancer Research</i> , 2006, 66, 10815-10823.	0.4	110
136	Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene. <i>Cell</i> , 2006, 125, 1269-1281.	13.5	380
137	High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. <i>Cancer Cell</i> , 2006, 9, 313-325.	7.7	404
138	Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities. <i>Cancer Research</i> , 2006, 66, 11502-11513.	0.4	187
139	Combined cDNA Array Comparative Genomic Hybridization and Serial Analysis of Gene Expression Analysis of Breast Tumor Progression. <i>Cancer Research</i> , 2006, 66, 4065-4078.	0.4	159
140	Discordance between functional magnetic resonance imaging during silent speech tasks and intraoperative speech arrest. <i>Journal of Neurosurgery</i> , 2005, 103, 267-274.	0.9	55
141	High-resolution genomic profiles of human lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9625-9630.	3.3	360
142	Common and Contrasting Genomic Profiles among the Major Human Lung Cancer Subtypes. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 11-24.	2.0	18
143	DNA amplification method tolerant to sample degradation. <i>Genome Research</i> , 2004, 14, 2357-2366.	2.4	79
144	High-Resolution Global Profiling of Genomic Alterations with Long Oligonucleotide Microarray. <i>Cancer Research</i> , 2004, 64, 4744-4748.	0.4	133

#	ARTICLE	IF	CITATIONS
145	Reprogramming of a melanoma genome by nuclear transplantation. <i>Genes and Development</i> , 2004, 18, 1875-1885.	2.7	321
146	Balanced-PCR amplification allows unbiased identification of genomic copy changes in minute cell and tissue samples. <i>Nucleic Acids Research</i> , 2004, 32, e76-e76.	6.5	55
147	High-resolution characterization of the pancreatic adenocarcinoma genome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9067-9072.	3.3	246
148	Molecular diversity of astrocytes with implications for neurological disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8384-8389.	3.3	193
149	Molecular characterization of the tumor microenvironment in breast cancer. <i>Cancer Cell</i> , 2004, 6, 17-32.	7.7	1,161
150	Nuclear cloning of embryonal carcinoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 13985-90.	3.3	104
151	Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis. <i>Blood</i> , 2004, 104, 785-785.	0.6	4
152	Isolated translocation of Wernicke's area to the right hemisphere in a 62-year-man with a temporo-parietal glioma. <i>American Journal of Neuroradiology</i> , 2004, 25, 130-3.	1.2	56
153	Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. <i>Cancer Research</i> , 2003, 63, 5352-6.	0.4	34
154	A Principal Components-Based Method for the Detection of Neuronal Activity Maps: Application to Optical Imaging. <i>NeuroImage</i> , 2000, 11, 313-325.	2.1	36
155	Concordance between Functional Magnetic Resonance Imaging and Intraoperative Language Mapping. <i>Stereotactic and Functional Neurosurgery</i> , 1999, 72, 95-102.	0.8	99
156	Extrageniculate vision in hemianopic humans: saccade inhibition by signals in the blind field. <i>Science</i> , 1990, 250, 118-121.	6.0	276
157	Saccade preparation inhibits reorienting to recently attended locations. <i>Journal of Experimental Psychology: Human Perception and Performance</i> , 1989, 15, 673-685.	0.7	446